We are live on ! Find out more
LLY icon

Eli Lilly

2,975 hedge funds and large institutions have $422B invested in Eli Lilly in 2023 Q3 according to their latest regulatory filings, with 276 funds opening new positions, 1,086 increasing their positions, 1,189 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 276 | Existing positions closed: 83

27% more funds holding in top 10

Funds holding in top 10: 242 → 307 (+65)

6% more funds holding

Funds holding: 2,816 → 2,975 (+159)

10% more capital inflows, than outflows

Capital inflows: $11.7B | Capital outflows: $10.7B

0.09% more ownership

Funds ownership: 82.62% → 82.72% (+0.09%)

7% less call options, than puts

Call options by funds: $4.49B | Put options by funds: $4.82B

9% less repeat investments, than reductions

Existing positions increased: 1,086 | Existing positions reduced: 1,189

Holders
2,975
Holders Change
+159
Holders Change %
+5.65%
% of All Funds
47.1%
Holding in Top 10
307
Holding in Top 10 Change
+65
Holding in Top 10 Change %
+26.86%
% of All Funds
4.86%
New
276
Increased
1,086
Reduced
1,189
Closed
83
Calls
$4.49B
Puts
$4.82B
Net Calls
-$331M
Net Calls Change
-$37.5M

LLY Hedge Fund Activity: Q3 2023 in Review

2,975 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q3 2023, worth a combined $422B — up 15% from $367B a quarter earlier.

Buyers outnumbered sellers: 276 funds opened new LLY positions and 83 closed out — a net gain of 193 holders — while 1,086 added to existing stakes and 1,189 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $857M. The largest seller was T. Rowe Price Associates, cutting an estimated $992M.

  • 2,975 institutional investors held Eli Lilly (LLY) as of Q3 2023, up from 2,816 in Q2 2023.
  • Funds reported $422B of Eli Lilly stock for Q3 2023, up 15% quarter-over-quarter.
  • 276 funds opened new Eli Lilly positions in Q3 2023 and 83 closed out, a net change of +193 holders.
  • The largest Eli Lilly buyer in Q3 2023 was JP Morgan Chase, an estimated $857M added.
  • The largest Eli Lilly seller in Q3 2023 was T. Rowe Price Associates, an estimated $992M sold.

Based on aggregated 13F filings for Q3 2023.